Company Profile
Mineralys Therapeutics Stock Price, News & Analysis
- Ticker:
- MLYS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
26.99 USD (+0.52%)
Close
Last updated: August 6, 2026
2.38B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MLYS closed up 0.52% at $26.99. No new same-company headline was identified in the current news window.
Company overview
Aldosterone-Driven Disease
Mineralys Therapeutics develops medicines for hypertension and related conditions driven by dysregulated aldosterone.
Lorundrostat
Lorundrostat is an oral, selective aldosterone-synthase inhibitor under FDA review as an add-on treatment for adults with uncontrolled or resistant hypertension.
Registrational Evidence
The application is supported by five clinical studies, including the Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. The Transform-HTN extension continues to collect longer-term safety and efficacy data.
Future catalysts
FDA PDUFA target action date for lorundrostat on December 22, 2026.
Potential U.S. launch of lorundrostat following approval.
Recent news
- 01
- 02
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Source: Mineralys Therapeutics
- 03
- 04
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Source: Mineralys Therapeutics
- 05
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Source: Mineralys Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Mineralys Therapeutics (MLYS)?
Mineralys Therapeutics (MLYS) most recently closed at 26.99 USD, a +0.52% move versus the previous session.
What is the market cap of Mineralys Therapeutics (MLYS)?
Mineralys Therapeutics currently has a market capitalization of 2.38B USD on BioPharmSignal.
What does Mineralys Therapeutics do?
Aldosterone-Driven Disease Mineralys Therapeutics develops medicines for hypertension and related conditions driven by dysregulated aldosterone. Lorundrostat Lorundrostat is an oral, selective aldosterone-synthase inhibitor under FDA review as an add-on treatment for adults with uncontrolled or resistant hypertension. Registrational Evidence The application...
On which exchange is MLYS stock listed?
Mineralys Therapeutics (MLYS) is associated with NASDAQ, United States, Biopharma.
What is lorundrostat?
FDA PDUFA target action date for lorundrostat on December 22, 2026.
Which conditions is Mineralys Therapeutics targeting with lorundrostat?
FDA PDUFA target action date for lorundrostat on December 22, 2026.
How does Mineralys Therapeutics describe recent progress with lorundrostat?
FDA PDUFA target action date for lorundrostat on December 22, 2026.
What is Aldosterone-Driven?
Aldosterone-Driven Disease Mineralys Therapeutics develops medicines for hypertension and related conditions driven by dysregulated aldosterone.